Clopidogrel Reloading in Patients With NSTEACS Undergoing Percutaneous Coronary Intervention on Chronic Clopidogrel Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01572129|
Recruitment Status : Unknown
Verified April 2012 by Patti Giuseppe, Campus Bio-Medico University.
Recruitment status was: Recruiting
First Posted : April 6, 2012
Last Update Posted : April 6, 2012
Patients who developed an acute coronary syndrome despite dual antiplatelet therapy with aspirin and clopidogrel may benefit from a further dose of clopidogrel before a percutaneous coronary intervention.
The aim of this study is to evaluate safety and effectiveness of clopidogrel reloading in patients on chronic clopidogrel therapy with acute coronary syndrome undergoing percutaneous coronary intervention.
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome Myocardial Infarction||Drug: Clopidogrel Drug: Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||240 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Care Provider)|
|Official Title:||Clopidogrel Reloading in Patients With Non-ST Elevation Acute Coronary Syndrome Undergoing PCI on Chronic Clopidogrel Therapy. Results of the ARMYDA RELOAD ACS (Antiplatelet Therapy for Reduction of MYocardial Damage During Angioplasty in Acute Coronary Syndrome) Randomized Trial.|
|Study Start Date :||November 2011|
|Estimated Primary Completion Date :||May 2012|
600 mg of clopidogrel loading dose 6-8 h before coronary angiogram, in addition to the chronic daily dose of 75 mg
600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
Other Name: Plavix
Placebo Comparator: Placebo
Placebo arm in addition to the chronic daily dose of 75 mg
Placebo in addition to the chronic daily dose of 75 mg
- Major Adverse Cardiovascular Events [ Time Frame: 30 days ]Death Myocardial Infarction Target Vessel Revascularization
- Bleeding Events [ Time Frame: 30 days ]Occurrence of vascular/bleeding complications, defined as: (a) major bleeding (intracranial bleeding or clinically overt bleeding associated with a decrease in haemoglobin >5 g/dL, according to the TIMI criteria); (b) minor bleeding (clinically overt haemorrhage associated with a fall in haemoglobin ≤5 g/dL); (c) entry-site complications (haematoma >5 cm, pseudoaneurysm or arteriovenous fistula)
- Grade of platelet residual reactivity [ Time Frame: Immediately before PCI (4-6h after randomization), 8h and 24h after PCI ]
Patient's response to clopidogrel at 3 different timing, assessed with VerifyNow P2Y12 Assays.
The first timing is immediately before PCI (4-6h after randomization), once accomplished the diagnostic angiogram.
The second and third timings are, respectively, 8h and 24h after PCI.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01572129
|Contact: Giuseppe Patti, MDemail@example.com|
|Vito Fazzi Hospital||Recruiting|
|Lecce, Italy, 73100|
|Principal Investigator: Giuseppe Colonna, MD|
|Sub-Investigator: Antonio Montinaro, MD|
|Campus Bio-Medico University||Recruiting|
|Rome, Italy, 00128|
|Principal Investigator: Giuseppe Patti, MD|
|Sub-Investigator: Vincenzo Vizzi, MD|
|Sub-Investigator: Elisabetta Ricottini, MD|
|Sub-Investigator: Fabio Mangiacapra, MD|
|Principal Investigator:||Giuseppe Patti, MD||Campus Bio-Medico University|